news
Pfizer’s breast cancer drug too expensive for NHS
3 February 2017 | By Niamh Marriott, Digital Editor
NICE has today published draft guidance which does not recommend Pfizer's breast cancer drug palbociclib for routine funding on the NHS...
List view / Grid view
Breast cancer
article
The prospects of medicinal plants in the treatment of breast cancer
Plants that have known medicinal properties are plentiful in Africa, and primary healthcare in the developing world has, since ancient times, relied heavily on their cultivation and use. Increasingly, too, the uses and effects of medicinal plants are becoming of interest globally.
news
Life-extending breast cancer drug approved by NICE
3 November 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE has said eribulin, which is also called Halaven and made by Eisai, should be an option for people with locally advanced or metastatic breast cancer...
news
Large study shows older breast cancer patients have worse outcomes
13 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Results showed that mortality was higher in patients over 70 who were either not tested with Oncotype DX or had a recurrence score result greater than 18...
news
Daiichi Sankyo Phase 1 HER2-targeting antibody drug safe and effective to treat breast cancer
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
DS-8201a is an investigational antibody drug conjugate comprised of a humanised anti-HER2 antibody attached by a peptide linker to a novel topoisomerase...
news
Novartis’ HR+/HER2- advanced breast cancer trial gives superior progression-free survival
10 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The results demonstrate that LEE011 plus letrozole reduced the risk of death or progression by 44%. The combination significantly improved PFS across...
news
Gene activity linked to breast cancer survival
18 August 2016 | By The Institute of Cancer Research, London
In a study of nearly 2000 patients, researchers found that women whose tumours had high F12 activity and low STC2 activity had a 32% chance of dying within 10 years, whereas those with low F12 activity and high STC2 activity had only a 10% chance of dying...
news
Lilly and Boehringer Ingelheim take on metastatic breast cancer
13 July 2016 | By Victoria White, Digital Content Producer
Lilly and Boehringer Ingelheim are to collaborate on a Phase Ib study of abemaciclib and BI 836845 in patients with HR+, HER2- metastatic breast cancer...
news
Denosumab may prevent breast cancer in women with BRCA1 gene mutation
20 June 2016 | By Victoria White, Digital Content Producer
Researchers have discovered that an existing medication, denosumab, may prevent breast cancer in women carrying a faulty BRCA1 gene...
news
Faslodex demonstrates superiority to Arimidex in Phase III study
27 May 2016 | By Victoria White, Digital Content Producer
The Phase III FALCON trial compared Faslodex to Arimidex for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women...
news
Long term benefits of breast cancer drug pertuzumab too uncertain says NICE
20 May 2016 | By Katie Sadler
NICE has announced it will not be recommending pertuzumab to treat HER2-positive breast cancer because it is uncertain of the long term benefits for patients.
news
The vascular remodelling effects of eribulin in advanced breast cancer
12 May 2016 | By Victoria White, Digital Content Producer
Newly published data validate the distinct vascular remodelling activity of Halaven (eribulin) compared to bevacizumab in breast tumour tissue...
news
Positive top-line results from the Phase III PALOMA-2 trial
20 April 2016 | By Victoria White, Digital Content Producer
Pfizer has announced positive top-line results from the Phase III PALOMA-2 trial for Ibrance (palbociclib) in breast cancer...
news
Lapatinib and trastuzumab shrinks HER2+ breast cancers within 11 days
11 March 2016 | By Victoria White
A trial has shown that lapatinib plus trastuzumab before surgery shrinks and may even destroy tumours in women with HER2+ breast cancer within 11 days. The EPHOS B trial studied 257 women with HER2 positive breast cancer in the short gap between initial diagnosis and surgery to remove their tumours.…
news
AstraZeneca’s Faslodex approved for new indication in the US
8 March 2016 | By Victoria White
The approval expands the use of Faslodex and offers additional options for US women with HR+, HER2- metastatic breast cancer…
